Acadia Pharmaceuticals INC: management transactions · United States · SEC (Form 4)

About Acadia Pharmaceuticals INC

ACADIA Pharmaceuticals Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq under the ticker ACAD, making it a closely watched name for investors focused on U.S. specialty healthcare and neuroscience. Headquartered in San Diego, California, the company develops and commercializes therapies for neurological disorders and rare diseases, with a strategy centered on underserved patient populations where treatment options are limited. Its corporate identity is rooted in neuroscience innovation and long-standing expertise in central nervous system disorders. ([acadia.com](https://acadia.com/en-us/about?utm_source=openai)) Acadia’s commercial portfolio is anchored by two key products. NUPLAZID (pimavanserin) is described by the company as the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. DAYBUE (trofinetide) is its second major commercial franchise: it is approved for Rett syndrome in adult and pediatric patients two years of age and older, with commercialization in the United States and Canada, and regulatory efforts underway in Europe. In December 2025, the FDA approved DAYBUE STIX, a powder formulation of trofinetide, and the product is now broadly available in the United States, adding convenience and formulation flexibility that may support adoption and persistence. ([acadia.com](https://acadia.com/en-us?utm_source=openai)) From a competitive standpoint, Acadia stands out as a focused neuroscience and rare-disease company. That specialization gives it meaningful scientific, regulatory and commercial barriers to entry, but also creates concentration risk because the business depends heavily on a small number of key assets. Recent company disclosures indicate that momentum has strengthened materially: 2025 total revenue exceeded $1 billion, and management raised 2026 guidance, signaling a more durable commercial base. In the first quarter of 2026, the company reiterated full-year guidance while reporting continued revenue growth. ([acadia.com](https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operating-overview?utm_source=openai)) Geographically, Acadia remains primarily U.S.-focused, but it is building an international footprint through Canada, Europe and certain named-patient or access pathways outside the U.S. The company is also actively advancing its pipeline, including remlifanserin for Alzheimer’s disease psychosis, ACP-711 for essential tremor, and additional CNS-focused programs. For French-speaking investors, ACAD therefore represents a specialty healthcare equity with a mix of established commercial assets, regulatory expansion potential, and clinical catalysts. ([acadia.com](https://acadia.com/en-us/about?utm_source=openai))